Clinical Trials Logo

Filter by:
NCT ID: NCT03946891 Withdrawn - Premature Birth Clinical Trials

Nebulized Furosemide in Premature Infants With Bronchopulmonary Dysplasia - A Cross Over Pilot Study of Its Efficacy and Safety

Start date: June 2016
Phase: Early Phase 1
Study type: Interventional

This is a prospective,randomized, cross over study comparing the efficacy and safety of nebulizedfurosemide with Intra Venous (IV)furosemide in preterm infants who areventilator-and oxygen dependent. Reviewing the patient census on Neo data by the Sub Investigator will identify the potential subjects. Subject will be randomized to either A arm or B arm. Subjects in the A arm will receive 1 mg/kg of inhaled furosemideQ 24 hours for 3 days. This will be followed by a washout period of a day followed by 1mg/kg of intravenous furosemide Q 24 hours for 3 days. Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.

NCT ID: NCT03946865 Withdrawn - Cancer Clinical Trials

Reiki Therapy - an Intervention in Hematology/Oncology Cancer Patients Hospitalized

Start date: July 10, 2019
Phase: N/A
Study type: Interventional

Researchers are trying to determine if offering and providing reiki therapy in hospitalized hematology/oncology cancer subjects has any effects on symptoms and feeling during the subjects hospital stay.

NCT ID: NCT03946462 Withdrawn - Acute Kidney Injury Clinical Trials

Nitric Oxide During CPB to Reduce AKI in Neonates

Start date: October 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, randomized, double-blind, placebo-controlled pilot study to investigate whether supplemental Nitric Oxide (NO) gas delivered during cardiac surgery with cardiopulmonary bypass (CPB) reduces the incidence and impact of acute kidney injury (AKI) in neonates undergoing surgery for congenital heart disease (CHD), when compared to placebo gas

NCT ID: NCT03943849 Withdrawn - Tooth Loss Clinical Trials

The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to examine and compare the effects of autogenous dental pulp tissue on bone formation in the extraction sockets as compared to commonly used particulate bone graft. The effects on bone formation will be examined using a wide variety of assays.

NCT ID: NCT03943706 Withdrawn - Tobacco Use Clinical Trials

E-Cigarette and Cigarette Nicotine Delivery and Abuse Liability in Cigarette Smokers and Dual Users

Start date: June 1, 2019
Phase:
Study type: Observational

The FDA has shown clear interest in strategies that will reduce the public health burden of tobacco use. One proposed strategy includes banning the sale of fully nicotinized cigarettes and only allowing VLNCs (Very Low Nicotine Cigarettes) to be sold. While there are concerns regarding the unintended consequences (e.g., black market sales of fully nicotinized cigarettes) of such bans, research is needed to understand how smokers and dual users will act in the potential market. The overall aim of the current research is to understand purchasing and product choice behaviors of tobacco/nicotine users if the proposed ban were to go into effect.

NCT ID: NCT03941496 Withdrawn - Clinical trials for Tuberculosis, Pulmonary

Azacytidine During Anti-tuberculosis Therapy

AZA
Start date: October 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Tuberculosis has been shown to make immune genes inaccessible and slows immune response The purpose of this research is to see if if azacitidine is safe and can return the ability of the body to resist tuberculosis (TB), a contagious infection that attacks the lungs. Individuals with tuberculosis are being asked to participate. Some will receive a drug to restore a host immunity while others can choose to receive standard of care. All patients will continue to receive standard of care tuberculosis therapy regardless of whether they chose to participate in the study. This study is a Phase Ib/IIa single-institution, open-label, non-randomized clinical trial of sub-cutaneous azacitidine in pulmonary TB patients during the continuation phase of ATT.

NCT ID: NCT03940248 Withdrawn - Breast Cancer Clinical Trials

Proton Accelerated Partial Breast Irradiation

APBI
Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

This prospective, non-randomized phase II study will evaluate the cosmetic outcome of using pencil beam scanning proton therapy for partial breast irradiation in patients diagnosed with early stage breast cancer. In addition the study will evaluate the acute and late toxicities, and the rates of ipsilateral breast tumor recurrence, both in situ and invasive disease. To qualify for the trial, patients must be 50 years or older and have stage 0 (carcinoma in situ) or stage IA or IIA invasive carcinoma of the breast with no evidence of metastatic disease. The tumor size must be 3cm or less. Women must have undergone a partial mastectomy with margins free of invasive cancer and at least a 2mm margin for in situ disease. Patients must have clinically node negative disease. Patients with invasive disease must also have nodal assessment performed with either sentinel lymph node biopsy or axillary lymph node dissection and patients must have pathologically node negative disease. Accelerated partial breast irradiation (APBI) will utilize pencil beam scanning proton therapy. Partial breast irradiation will be delivered twice a day, at least 6 hours apart, over 5 treatment days. This trial is designed to accrue 21 patients over a period of three years.

NCT ID: NCT03939780 Withdrawn - Healthy Clinical Trials

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

Start date: January 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to identify a new radioligand for imaging of tauopathy in Alzheimer's disease through direct comparisons of two potential candidates, [18F]RO-948 (formerly known as [18F]6958948) and [18F]MK-6240, and demonstration of the candidates' absence of off-target binding.

NCT ID: NCT03939364 Withdrawn - Leukoplakia, Oral Clinical Trials

This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions

Start date: January 2022
Phase: Phase 1
Study type: Interventional

This study will be the first study investigating the safety, pharmacokinetics (PK), and efficacy of SBS-101 on oral pre-malignant lesions. As such, no clinical data has yet been generated using SBS-101 oral adhesive film.

NCT ID: NCT03938922 Withdrawn - Parkinson Disease Clinical Trials

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.